Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Амлодипин в лечении хронической сердечной недостаточности
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Прогноз при хронической сердечной недостаточности (ХСН) остается неблагоприятным, что требует разработки новых способов лечения этого состояния. Данные последних лет свидетельствуют о том, что при ряде форм ХСН с сохраненной систолической функцией левого желудочка (ЛЖ) добавление к стандартной схеме терапии амлодипина ассоциировано с дополнительными клиническими преимуществами. Представлены результаты применения амлодипина у женщин с ХСН и сохраненной фракцией выброса ЛЖ.
Ключевые слова: хроническая сердечная недостаточность, амлодипин, систолическая функция, левый желудочек, эстрогены.
Ключевые слова: хроническая сердечная недостаточность, амлодипин, систолическая функция, левый желудочек, эстрогены.
________________________________________________
The prognosis of chronic heart failure (CHF) remains poor, requiring new treatment options for this condition. Recent data suggest that the addition of amlodipine to the standard therapy regimen for a number of forms of CHF with preserved left ventricular (LV) systolic function is associated with additional clinical benefits. The results of using amlodipine in women with CHF and preserved LV ejection fraction are given.
Key words: chronic heart failure, amlodipine, systolic function, left ventricle, estrogens.
Полный текст
Список литературы
1. Elkayam U, Amin J, Mehra A et al. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation 1990; 82: 1954–61.
2. Barjon JN, Rouleau J-L, Bichet D et al. Chronic renal and neurohumoral effects of the calcium entry blocker nisoldipine in patients with congestive heart failure. J Am Coll Cardiol 1987; 9: 622–30.
3. Goldstein RE, Boccuzzi SJ, Cruess D. Adverse Experience Committee, Multicenter Diltiazem Postinfarction Research Group. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. Circulation 1991; 83: 52–60.
4. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988; 319: 385–92.
5. Packer M, Kessler PD, Lee WH. Calcium-channel blockade in the management of severe chronic congestive heart failure: a bridge too far. Circulation 1987; 75 (Suppl. V): V56–64.
6. Packer M, Nicod P, Khandheria BR et al. Randomized, multicenter, double-blind, placebo-controlled evaluation of amlodipine in patients with mild-to-moderate heart failure. J Am Coll Cardiol 1991; 17 (Suppl. A): 274A.
7. Smith WB, DeAbate AC, Gollub SB et al. Beneficial long-term hemodynamic and clinical effects of amlodipine in chronic heart failure: results of a multicenter randomized, double-blind, placebo-controlled, dose-ranging study. Circulation 1994; 90 (Suppl.): I–603.
8. Levy D, Larson M, Vasan R et al. The progression from hypertension to congestive heart failure. JAMA 1996; 275: 1557–662.
9. Chen YT, Vaccarino V, Williams CS et al. Risk factors for heart failure in the elderly: a prospective community based study. Am J Med 1999; 106: 605–9.
10. Hoffman R, Psaty BM, Kronmal RA. Modifiable risk factors for incidence of heart failure in the Coronary Artery Surgery Study. Arch Intern Med 1994; 154: 417–24.
11. Jessup M, Pina I. Is it important to examine gender differences in the epidemiology and outcome of severe heart failure? J Thorac Cardiovasc Surg 2004; 127: 1247–52.
12. Weinberg E, Thienelt C, Katz S et al. Gender differences in molecular remodeling in pressure overload hypertrophy. J Am Coll Cardiol 1999; 34: 264–73.
13. Pfeffer J, Pfeffer M, Fletcher P et al. Favorable effects of therapy on cardiac performance in spontaneously hypertensive rats. Am J Physiol 1982; 242: H776–84.
14. Carroll J, Carroll E, Feldman T et al. Sex-associated differences in left ventricular function in aortic stenosis of the elderly. Circulation 1992; 86: 1099–107.
15. Aurigemma G, Gaasch W. Gender differences in older patients with pressure-overload hypertrophy of the left ventricle. Cardiology 1995; 86: 310–7.
16. Mendez L, Davidoff R, Cupples L et al. Congestive heart failure in patients with coronary artery disease: the gender paradox. Am Heart J 1997; 134: 207–12.
17. Krumholz H, Larson M, Levy D. Sex differences in cardiac adaptation to isolated systolic hypertension. Am J Cardiol 1993; 72: 310–3.
18. Packer M, Lee WH, Medina N et al. Prognostic importance of the immediate hemodynamic response to nifedipine in patients with severe left ventricular dysfunction. J Am Coll Cardiol 1987; 10: 1303–11.
19.Witchitz S, Haiat R, Tarrade T et al. Accidents cardio-vasculaires au cours des traitements par le verapamil: a propos de 6 observations. Nouv Press Med 1975; 4: 337–8.
20. Elkayam U, Weber L, McKay C et al. Spectrum of acute hemodynamic effects of nifedipine in severe congestive heart failure. Am J Cardiol 1985; 56: 560–6.
21. Packer M, Lee WH, Medina N, Yushak M. Comparative negative inotropic effects of nifedipine and diltiazem in patients with severe left ventricular dysfunction. Circulation 1985; 72 (Suppl. III): III–275.
22. Ferlinz J, Gallo CT. Responses of patients in heart failure to long-term oral verapamil administration. Circulation 1984; 70 (Suppl. II): II–305.
23. Kloner R, Sowers J, DiBona G et al. Sex- and age-related antihypertensive effects of amlodipine. Am J Cardiol 1996; 77: 713–22.
24. Packer M, O`Connor C, Ghali J et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996; 335: 1107–14.
25. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (третий пересмотр). Доступно на http://medic.ossn.ru/upload/ossn_pdf/Recomend/Guidelines%20SSHF%20rev.3.01%202010.pdf
2. Barjon JN, Rouleau J-L, Bichet D et al. Chronic renal and neurohumoral effects of the calcium entry blocker nisoldipine in patients with congestive heart failure. J Am Coll Cardiol 1987; 9: 622–30.
3. Goldstein RE, Boccuzzi SJ, Cruess D. Adverse Experience Committee, Multicenter Diltiazem Postinfarction Research Group. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. Circulation 1991; 83: 52–60.
4. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988; 319: 385–92.
5. Packer M, Kessler PD, Lee WH. Calcium-channel blockade in the management of severe chronic congestive heart failure: a bridge too far. Circulation 1987; 75 (Suppl. V): V56–64.
6. Packer M, Nicod P, Khandheria BR et al. Randomized, multicenter, double-blind, placebo-controlled evaluation of amlodipine in patients with mild-to-moderate heart failure. J Am Coll Cardiol 1991; 17 (Suppl. A): 274A.
7. Smith WB, DeAbate AC, Gollub SB et al. Beneficial long-term hemodynamic and clinical effects of amlodipine in chronic heart failure: results of a multicenter randomized, double-blind, placebo-controlled, dose-ranging study. Circulation 1994; 90 (Suppl.): I–603.
8. Levy D, Larson M, Vasan R et al. The progression from hypertension to congestive heart failure. JAMA 1996; 275: 1557–662.
9. Chen YT, Vaccarino V, Williams CS et al. Risk factors for heart failure in the elderly: a prospective community based study. Am J Med 1999; 106: 605–9.
10. Hoffman R, Psaty BM, Kronmal RA. Modifiable risk factors for incidence of heart failure in the Coronary Artery Surgery Study. Arch Intern Med 1994; 154: 417–24.
11. Jessup M, Pina I. Is it important to examine gender differences in the epidemiology and outcome of severe heart failure? J Thorac Cardiovasc Surg 2004; 127: 1247–52.
12. Weinberg E, Thienelt C, Katz S et al. Gender differences in molecular remodeling in pressure overload hypertrophy. J Am Coll Cardiol 1999; 34: 264–73.
13. Pfeffer J, Pfeffer M, Fletcher P et al. Favorable effects of therapy on cardiac performance in spontaneously hypertensive rats. Am J Physiol 1982; 242: H776–84.
14. Carroll J, Carroll E, Feldman T et al. Sex-associated differences in left ventricular function in aortic stenosis of the elderly. Circulation 1992; 86: 1099–107.
15. Aurigemma G, Gaasch W. Gender differences in older patients with pressure-overload hypertrophy of the left ventricle. Cardiology 1995; 86: 310–7.
16. Mendez L, Davidoff R, Cupples L et al. Congestive heart failure in patients with coronary artery disease: the gender paradox. Am Heart J 1997; 134: 207–12.
17. Krumholz H, Larson M, Levy D. Sex differences in cardiac adaptation to isolated systolic hypertension. Am J Cardiol 1993; 72: 310–3.
18. Packer M, Lee WH, Medina N et al. Prognostic importance of the immediate hemodynamic response to nifedipine in patients with severe left ventricular dysfunction. J Am Coll Cardiol 1987; 10: 1303–11.
19.Witchitz S, Haiat R, Tarrade T et al. Accidents cardio-vasculaires au cours des traitements par le verapamil: a propos de 6 observations. Nouv Press Med 1975; 4: 337–8.
20. Elkayam U, Weber L, McKay C et al. Spectrum of acute hemodynamic effects of nifedipine in severe congestive heart failure. Am J Cardiol 1985; 56: 560–6.
21. Packer M, Lee WH, Medina N, Yushak M. Comparative negative inotropic effects of nifedipine and diltiazem in patients with severe left ventricular dysfunction. Circulation 1985; 72 (Suppl. III): III–275.
22. Ferlinz J, Gallo CT. Responses of patients in heart failure to long-term oral verapamil administration. Circulation 1984; 70 (Suppl. II): II–305.
23. Kloner R, Sowers J, DiBona G et al. Sex- and age-related antihypertensive effects of amlodipine. Am J Cardiol 1996; 77: 713–22.
24. Packer M, O`Connor C, Ghali J et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996; 335: 1107–14.
25. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (третий пересмотр). Доступно на http://medic.ossn.ru/upload/ossn_pdf/Recomend/Guidelines%20SSHF%20rev.3.01%202010.pdf
Авторы
С.Н.Терещенко, И.В.Жиров*
ФГУ РКНПК Минздравсоцразвития РФ, Москва
*izhirov@mail.ru
ФГУ РКНПК Минздравсоцразвития РФ, Москва
*izhirov@mail.ru
________________________________________________
S.N.Tereshchenko, I.V.Zhirov*
Russian Cardiology Research-and-Production Complex, Ministry of Health and Social Development of the Russian Federation, Moscow
*izhirov@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.